We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

MINDRAY In-Vitro Diagnostics

As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App




Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

By LabMedica International staff writers
Posted on 04 Mar 2021
Print article
Illustration
Illustration
Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell analysis and further explore AI technology in vitro diagnostics.

Through this cooperation, the two parties will further develop blood cell morphology testing equipment and system applications with world-class imaging quality and cell recognition capabilities. Large-scale production in the future is expected to relieve the work pressure faced by primary endoscopy physicians, and improve the diagnosis and diagnosis of blood diseases.

Tencent AI Lab will use machine learning, computer vision and other cutting-edge algorithms and the experience of its research scientists, Tencent Cloud’s comprehensive solutions, combined with Mindray Medical’s expertise in slide processing, imaging systems, integrated design, and clinical experts, massive data and other aspects, to jointly develop an automated blood cell analyzer in order to further improve accuracy in results. The automated blood cell analyzer will detect cell quality changes and have high levels of cell identification capability. At the same time, it will provide a cost advantage as compared to rival products with higher prices.

In addition to morphological testing, Tencent AI Lab will also work with Mindray Medical to explore the integration and application of AI technology in other areas of in vitro diagnostics, such as urine analysis, smart laboratory, and in vitro diagnostic big data, in order to provide better quality medical equipment and services.

“AI+Medical/Pharmaceutical" is one of Tencent's AI Lab's long-term core research directions. We are very happy to cooperate with industry top partners like Mindray to enable technology to help medical care, assist doctors, and serve patients,” said Yang Wei, General Manager of Tencent AI Lab.

“With Mindray’s deep understanding of clinical needs and accumulation of detection technology over the years, and Tencent’s leading exploration in artificial intelligence technology, The results of the cooperation between the two parties will greatly improve the ability of clinical intelligent detection,” said Yan Huawen, General Manager of Mindray’s IVD Division.

Related Links:
Mindray
Tencent AI Lab


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.